The Atopic Dermatitis Drugs Market was valued at USD 14.93 billion in 2024 and is set to reach USD 29.43 billion by 2032, with a CAGR of 8.92%. Improved treatments and rising disease prevalence, especially in children, are driving market growth. Major companies include Sanofi, Regeneron, AbbVie, Pfizer, and more.

The U.S. Atopic Dermatitis Drugs Market was valued at USD 5.61 billion in 2024, expected to reach USD 10.78 billion by 2032. Biologics lead the market with a 39.08% share, while topical treatments dominate at 40.12%. Hospital pharmacies hold a 62.31% market share, with fast-growing trends in other pharmacies.

North America led the atopic dermatitis drugs market in 2024 with a 46.20% market share, driven by high disease prevalence and advanced healthcare infrastructure. Asia Pacific shows the fastest growth with a 9.59% CAGR, fueled by rising healthcare expenditure and improving access to dermatological care.

Recent developments include FDA approval for Dupixent by Sanofi and Regeneron for chronic spontaneous urticaria treatment. AbbVie reported positive Phase 3b/4 trial results for upadacitinib in atopic dermatitis. The report also covers disease prevalence, prescription patterns, healthcare spending, biologics uptake, and competitive landscape metrics.

Read more at GlobeNewswire: Atopic Dermatitis Drugs Market to Reach $29.43 Billion by